These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
58 related articles for article (PubMed ID: 21631692)
1. Reduced delays in time to first HIV consultation after diagnosis in France in the antiretroviral therapy era: the possible role of a free care system. Suzan-Monti M; Fugon L; Marcellin F; Carrieri MP; Lert F; Obadia Y; Spire B; HIV Med; 2011 Jul; 12(6):383-4. PubMed ID: 21631692 [No Abstract] [Full Text] [Related]
2. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). Kapogiannis BG; Soe MM; Nesheim SR; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M Pediatrics; 2008 May; 121(5):e1229-39. PubMed ID: 18450865 [TBL] [Abstract][Full Text] [Related]
3. A shift in referral patterns for HIV/AIDS patients. Fournier PO; Savageau JA; Baldor RA J Fam Pract; 2008 Feb; 57(2):E1-9. PubMed ID: 18248723 [TBL] [Abstract][Full Text] [Related]
4. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. Bozzette SA; Joyce G; McCaffrey DF; Leibowitz AA; Morton SC; Berry SH; Rastegar A; Timberlake D; Shapiro MF; Goldman DP; N Engl J Med; 2001 Mar; 344(11):817-23. PubMed ID: 11248159 [TBL] [Abstract][Full Text] [Related]
5. Pediatric HIV costs across three treatment eras from 1986 to 2007. Wilson LS; Basu R; Christenson M; Hensic L; Paoli C; Wara D; Moskowitz JT Pediatrics; 2010 Sep; 126(3):e541-9. PubMed ID: 20696721 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422 [TBL] [Abstract][Full Text] [Related]
7. Late presentation of HIV/AIDS patients: a Caribbean problem. Bartholomew C; Boyce G; Fraser O; Sebro A; Telfer-Baptiste M; Labastide S AIDS Patient Care STDS; 2011 Dec; 25(12):707-8. PubMed ID: 21457053 [No Abstract] [Full Text] [Related]
8. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs. Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317 [TBL] [Abstract][Full Text] [Related]
9. Delayed first consultation after diagnosis of HIV infection in Cameroon. Marcellin F; Abé C; Loubière S; Boyer S; Blanche J; Koulla-Shiro S; Ongolo-Zogo P; Moatti JP; Spire B; Carrieri MP; AIDS; 2009 May; 23(8):1015-9. PubMed ID: 19339871 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of HIV post-exposure prophylaxis in France. Herida M; Larsen C; Lot F; Laporte A; Desenclos JC; Hamers FF AIDS; 2006 Aug; 20(13):1753-61. PubMed ID: 16931940 [TBL] [Abstract][Full Text] [Related]
11. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. Bezemer D; de Wolf F; Boerlijst MC; van Sighem A; Hollingsworth TD; Prins M; Geskus RB; Gras L; Coutinho RA; Fraser C AIDS; 2008 May; 22(9):1071-7. PubMed ID: 18520351 [TBL] [Abstract][Full Text] [Related]
12. Sarcoidosis in HIV-infected patients in the era of highly active antiretroviral therapy. Foulon G; Wislez M; Naccache JM; Blanc FX; Rabbat A; Israël-Biet D; Valeyre D; Mayaud C; Cadranel J Clin Infect Dis; 2004 Feb; 38(3):418-25. PubMed ID: 14727215 [TBL] [Abstract][Full Text] [Related]
13. Effect of anxiety symptoms on adherence to highly active antiretroviral therapy in HIV-infected women. Roux P; Carrieri MP; Michel L; Fugon L; Marcellin F; Obadia Y; Spire B J Clin Psychiatry; 2009 Sep; 70(9):1328-9. PubMed ID: 19818261 [No Abstract] [Full Text] [Related]
14. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. Long L; Fox M; Sanne I; Rosen S AIDS; 2010 Mar; 24(6):915-9. PubMed ID: 20042849 [TBL] [Abstract][Full Text] [Related]
15. Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon. Boyer S; Eboko F; Camara M; Abé C; Nguini ME; Koulla-Shiro S; Moatti JP AIDS; 2010 Jan; 24 Suppl 1():S5-15. PubMed ID: 20023440 [TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV. Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534 [TBL] [Abstract][Full Text] [Related]
17. [Infected abroad--risk factor for late HIV diagnosis]. Oppenheimer B; Arneborn M; Velicko I; Blaxhult A Lakartidningen; 2008 Jan 30-Feb 5; 105(5):292-4. PubMed ID: 18368959 [No Abstract] [Full Text] [Related]
18. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Kumarasamy N; Solomon S; Chaguturu SK; Cecelia AJ; Vallabhaneni S; Flanigan TP; Mayer KH Clin Infect Dis; 2005 Nov; 41(10):1525-8. PubMed ID: 16231268 [TBL] [Abstract][Full Text] [Related]
19. The HIV pharmacy: managing quality and costs of HIV care. Valenti WM AIDS Read; 2002 Nov; 12(11):486-8. PubMed ID: 12498153 [No Abstract] [Full Text] [Related]
20. Providing antiretroviral therapy for HIV infection. Steinbrook R N Engl J Med; 2001 Mar; 344(11):844-6. PubMed ID: 11248164 [No Abstract] [Full Text] [Related] [Next] [New Search]